Minimizing bias due to confounding by indication in comparative effectiveness research: The importance of restriction

JAMA

Volumn 304, Issue 8, 2010, Pages 897-898

  Psaty, Bruce M ^a,b,c   Siscovick, David S ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANGINA PECTORIS; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; CONFOUNDING VARIABLE; DISEASE COURSE; HEALTH CARE POLICY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HORMONAL THERAPY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; VEIN THROMBOSIS; ARTICLE; CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; OBSERVATION; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STATISTICS;

ANTIHYPERTENSIVE AGENTS; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR DISEASES; COMPARATIVE EFFECTIVENESS RESEARCH; CONFOUNDING FACTORS (EPIDEMIOLOGY); DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; OBSERVATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS;

EID: 77955953084     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1205     Document Type: Note

References (10)

1. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA. 2008;300(20):2417-2419.
2. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356(18):1895-1896.
3. Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA. 2004;292(13):1581-1587.
4. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
5. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539-540.
6. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274(8):620-625.
7. Psaty BM, Koepsell TD, Lin DY, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749-754.
8. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534-2544. (Pubitemid 37430155)
9. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330(26):1852-1857.
10. Boger-Megiddo I, Heckbert SR, Weiss NS, et al. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ. 2010;340:c103.